Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2021 Filed Sep 13, 2021 20:17 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 5,000 | $297.33 | $1,486,650.00 |
DisclosureSEC source: 0001127602-21-025210 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,286 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:17 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-21-025210 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 16:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $292.16 | $434,441.92 |
DisclosureSEC source: 0001127602-21-024939 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,959 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 19:01 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $287.30 | $689,526.96 |
DisclosureSEC source: 0001127602-21-024743 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,879 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:28 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $288.41 | $432,615.00 |
DisclosureSEC source: 0001127602-21-024859 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,731 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 16:08 UTC |
Burt CarolDirector
|
GiftResMed Common Stock | 347 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024566 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Carol Burt Hilliard Trust Disclosed balance after: 14,595 F1 · kind: Gift of shares to The Colorado chapter of The Nature Conservancy, a nonprofit charitable 501(c)(3) organization. Ms. Burt has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 23:05 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,543 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-024177 · form4.xml · derivative · entry 5 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: ResMed Common Stock · 5,543 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 23:05 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,193 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-024177 · form4.xml · derivative · entry 4 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,543 Underlying: ResMed Common Stock · 5,193 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 23:05 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 10,736 | $281.73 | $3,024,653.28 |
DisclosureSEC source: 0001127602-21-024177 · form4.xml · nonDerivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,786 Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 23:05 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 5,543 | $57.76 | $320,163.68 |
DisclosureSEC source: 0001127602-21-024177 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 23:05 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 5,193 | $57.76 | $299,947.68 |
DisclosureSEC source: 0001127602-21-024177 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:05 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 4,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024094 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,786 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:01 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 4,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024092 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,231 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 15:59 UTC |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 2,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024090 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,695 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:00 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 2,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024091 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,446 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 15:57 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 18,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024088 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,611 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Includes 33.4591 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 15:58 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024089 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,279 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 15:56 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 5,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024087 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,149 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Oct 12, 2021 22:19 UTC Amendment |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 1,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026982 · form4a.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,611 F2 · kind: Represents performance-based restricted stock units granted on July 1, 2020 and reportable back on August 19, 2021. The shares were earned when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Oct 12, 2021 22:19 UTC Amendment |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026982 · form4a.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,279 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 18:06 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-023841 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 18:06 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $275.57 | $2,204,560.00 |
DisclosureSEC source: 0001127602-21-023841 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,767 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 18:06 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-023841 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 22:39 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 36,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023942 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,966 F1 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Unitrust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:21 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $278.05 | $695,125.00 |
DisclosureSEC source: 0001127602-21-023535 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:26 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $269.38 | $400,568.06 |
DisclosureSEC source: 0001127602-21-023038 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,413 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 01:30 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $268.94 | $645,463.68 |
DisclosureSEC source: 0001127602-21-022817 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,538 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 15:27 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $269.00 | $403,500.00 |
DisclosureSEC source: 0001127602-21-022839 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,165 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:36 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-022126 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:36 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $248.00 | $1,984,000.00 |
DisclosureSEC source: 0001127602-21-022126 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,767 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:36 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-022126 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 22:10 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $248.46 | $621,150.00 |
DisclosureSEC source: 0001127602-21-021895 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,502 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 19:46 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $247.12 | $367,467.44 |
DisclosureSEC source: 0001127602-21-021673 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 17:21 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $245.72 | $368,580.00 |
DisclosureSEC source: 0001127602-21-021160 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,665 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 15:59 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $247.30 | $593,513.04 |
DisclosureSEC source: 0001127602-21-021468 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,938 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:04 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-020062 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:04 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $232.10 | $1,856,800.00 |
DisclosureSEC source: 0001127602-21-020062 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,767 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:04 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-020062 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 13:53 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $212.84 | $532,100.00 |
DisclosureSEC source: 0001127602-21-019756 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 17:10 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $207.00 | $307,809.00 |
DisclosureSEC source: 0001127602-21-019336 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,387 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 66.72 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 18:39 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $206.03 | $494,475.36 |
DisclosureSEC source: 0001127602-21-018674 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,338 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:56 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $207.13 | $310,695.00 |
DisclosureSEC source: 0001127602-21-018662 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,165 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 77.2962 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 21, 2021 Filed May 24, 2021 15:13 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $202.01 | $484,824.00 |
DisclosureSEC source: 0001127602-21-017859 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,738 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 92.27 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 17, 2021 Filed May 19, 2021 16:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-017340 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 17, 2021 Filed May 19, 2021 16:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-017340 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 65.09 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 17, 2021 Filed May 19, 2021 16:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $195.00 | $1,560,000.00 |
DisclosureSEC source: 0001127602-21-017340 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,766 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 10, 2021 Filed May 11, 2021 23:07 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $196.00 | $490,000.00 |
DisclosureSEC source: 0001127602-21-016280 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,502 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 80.54 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:23 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $190.50 | $283,273.50 |
DisclosureSEC source: 0001127602-21-015196 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,807 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 03, 2021 Filed May 4, 2021 17:55 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $190.50 | $285,750.00 |
DisclosureSEC source: 0001127602-21-015115 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,588 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 19:12 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 964 | $207.45 | $199,981.80 |
DisclosureSEC source: 0001127602-21-013832 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 210,407 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.